Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 17 October 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Infliximab trough levels predict treatment failure during maintenance

Infliximab trough levels at induction to predict treatment failure during maintenance, reports the latest issue of the Inflammatory Bowel Diseases.

News image

Infliximab is indicated for the treatment of inflammatory bowel diseases (IBD).

Nevertheless, loss of response to infliximab is reported in up to 10% to 30% of patients within the first year of treatment.

Dr Claire Liefferinckx and colleagues evaluated the impact of the pharmacokinetics of infliximab at induction on treatment failure.

This is a longitudinal cohort study on 269 patients with IBD treated with infliximab in a single center.

A total of 2331 blood samples were prospectively collected from 2007 until 2015 with a retrospective analysis of clinical data.

Median infliximab trough levels at induction was lower when patients had been previously exposed to anti–tumor necrosis factor
Inflammatory Bowel Diseases

Infliximab trough levels were measured by enzyme-linked immunosorbent assay.

Antibodies to infliximab were measured by drug-sensitive bridging assay.

During follow-up, patients were defined according to treatment outcome.

At week 6, median infliximab trough levels in patients requiring a switch to another treatment due to loss of response was lower than in patients with long-term response, and in patients responding to optimization.

At week 2, median infliximab trough level was lower in the loss of response switched group compared with the long-term responders but no significant difference was reached with the loss of response optimized group.

In the loss of response switched group, median infliximab trough levels at induction was significantly lower when patients had been previously exposed to anti–tumor necrosis factor compared with naive patients.

Dr Liefferinckx's team concludes, "This study suggests that patients who do not respond to any optimization strategy have lower infliximab trough levels during induction at week 6."

"Infliximab trough levels measured early on at induction might predict treatment failure to infliximab during maintenance."

Inflamm Bowel Dis 2017: 23(8): 1371–1381
15 August 2017

Go to top of page Email this page Email this page to a colleague

 16 October 2017 
Breastfeeding and the risk of IBD
 16 October 2017 
Colorectal cancer screening and postpolypectomy surveillance colonoscopy
 16 October 2017 
Continuity of care after colorectal surgery
 13 October 2017 
Treating patients with HCV and severe renal impairment
 13 October 2017 
Blood pressure management during abdominal surgery
 13 October 2017 
Food elimination diets for eosinophilic esophagitis
 12 October 2017 
Global recurrence of H. pylori
 12 October 2017 
Colonoscopy in an organized colorectal cancer screening program 
 12 October 2017 
Predicting advanced fibrosis in chronic hepatitis B
 11 October 2017 
Fecal microbiota transplantation for ulcerative colitis
 11 October 2017 
Sexual functioning in Hep C
 11 October 2017 
Ulcerative proctitis in pediatric-onset UC
 10 October 2017 
Quality standards in upper gastrointestinal endoscopy
 10 October 2017 
Eosinophilic esophagitis and swallowed topical corticosteroids
 10 October 2017 
Follow-up of positive results on fecal blood tests
 09 October 2017 
Diverticulitis and emergency department burden
 09 October 2017 
Global recurrence rate of H. pylori
 09 October 2017 
Clostridium difficile infection after ileostomy reversal
 06 October 2017 
Predicting nontreatment for Hep C
 06 October 2017 
Cow's milk–based formula and development of celiac disease
 06 October 2017 
Propofol for outpatient colonoscopy
 05 October 2017 
Pediatric candidates on the transplant wait list
 05 October 2017 
Incidence of sepsis in the USA
 05 October 2017 
Quality of life after chemoradiation in rectal cancer
 04 October 2017 
Peptic ulcer disease diagnosed in acute upper endoscopy
 04 October 2017 
Clinical practice guidelines in colon cancer
 04 October 2017 
Rural residence and risk of IBD
 03 October 2017 
Antibody tests and detecting celiac disease
 03 October 2017 
Novel candidate risk genes for IBD
 03 October 2017 
Environmental factors and IBD
 02 October 2017 
Full publication of Gastroenerology abstracts
 02 October 2017 
Interferon-free therapy in advanced liver disease
 02 October 2017 
Burden of NAFLD with advanced fibrosis in the USA
 29 September 2017 
Laparoscopic surgery use in Medicare patients with colon cancer
 29 September 2017 
Inpatient Gastroenterology training experience
 29 September 2017 
Proteomic analysis of IBD
 28 September 2017 
Social networking-based discussion group by ERCP doctors
 28 September 2017 
Incidence of biopsy-verified celiac disease
 28 September 2017 
Medication nonadherence and health care costs
 27 September 2017 
Predictors of nonadherence in IBD
 27 September 2017 
Hep C treatment in the era of direct-acting anti-viral agents
 27 September 2017 
Function of trypsin-3 in IBS
 26 September 2017 
Chronic pancreatitis and pancreatic cancer risk
 26 September 2017 
Factors associated with the risk of metachronous gastric neoplasm
 26 September 2017 
Treatment of hyperactive delirium in advanced cancer
 25 September 2017 
Lenalidomide for advanced liver cancer
 25 September 2017 
Silibinin nanoparticles inhibit HCV infection
 25 September 2017 
Asthma and IBD development
 22 September 2017 
Perforation after colonic endoscopic mucosal resection
 22 September 2017 
Medical management and colectomy rates
 22 September 2017 
MRI for liver metastatic colorectal cancer
 21 September 2017 
Adenomatous colorectal polyps in young cancer survivors
 21 September 2017 
Predicting mucosal healing in treated celiac disease patients
 21 September 2017 
Antireflux surgery and recurrence of GERD
 20 September 2017 
Rifaximin and spontaneous bacterial peritonitis in cirrhosis
 20 September 2017 
Omega-3 PUFA and colorectal cancer survival
 20 September 2017 
Beta-blockers and cardiopulmonary exercise testing in liver disease
 19 September 2017 
Birth outcomes in children fathered by men treated with azathioprine
 19 September 2017 
Risk of death and statins in alcoholic cirrhosis
 19 September 2017 
Hospital-readmission risk

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us